Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07520214

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

Status
Enrolling By Invitation
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
9 (estimated)
Sponsor
Beijing Neurosurgical Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.

Conditions

Interventions

TypeNameDescription
BIOLOGICALmRNA vaccine: GV-907、GV-108Eligible patients will receive intradermal injections of cancer vaccines

Timeline

Start date
2025-09-10
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2026-04-09
Last updated
2026-04-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07520214. Inclusion in this directory is not an endorsement.